Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Rises By 243.1%

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw a significant increase in short interest in January. As of January 31st, there was short interest totalling 1,536,000 shares, an increase of 243.1% from the January 15th total of 447,700 shares. Based on an average trading volume of 2,008,300 shares, the short-interest ratio is presently 0.8 days.

Bayer Aktiengesellschaft Stock Performance

BAYRY stock traded up $0.07 during trading on Wednesday, reaching $5.54. The company had a trading volume of 648,213 shares, compared to its average volume of 1,169,202. The company has a market cap of $21.77 billion, a price-to-earnings ratio of -21.31 and a beta of 1.04. Bayer Aktiengesellschaft has a twelve month low of $4.79 and a twelve month high of $8.58. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.81 and a current ratio of 1.32. The firm has a 50-day simple moving average of $5.23 and a 200-day simple moving average of $6.44.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. The firm had revenue of $10.96 billion during the quarter. As a group, sell-side analysts expect that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.